查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2138125

2034年腫瘤精準醫療和液態生物檢體市場預測－按生物標記類型、癌症類型、技術、應用、最終用戶和地區分類的全球分析

Oncology Precision Medicine & Liquid Biopsy Market Forecasts to 2034 - Global Analysis By Biomarker Type, Cancer Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球腫瘤精準醫療和液態生物檢體市場規模將達到 67 億美元，在預測期內複合年成長率將達到 25.2%，到 2034 年將達到 407 億美元。

腫瘤學中的精準醫療和液態生物檢體將個人化癌症治療與先進的分子檢測相結合，以腫瘤的生物學特徵為依據制定治療決策。此方法利用基因組資訊、生物標記和液態生物檢體技術來檢測具有臨床意義的突變，並評估癌症的長期進展。透過分析血液中循環的腫瘤DNA及其相關標記物，液態生物檢體提供了一種微創的診斷、治療選擇和後續觀察工具。這些技術的結合能夠實現個人化治療策略、持續評估，並在癌症管理的各個階段改善臨床決策。

根據世界衛生組織/國際癌症研究機構的數據，全球每年約有2,060萬例新增癌症病例和近1,000萬人死於癌症。這顯示癌症給人類帶來了巨大的疾病負擔，並凸顯了先進腫瘤診斷技術和個人化治療方案的必要性。

對個人化癌症治療的需求日益成長

對個人化癌症治療日益成長的需求正在推動腫瘤精準醫療和液態生物檢體市場的擴張。精準腫瘤學幫助醫生確定與腫瘤分子和基因特徵相符的治療方案，從而支持更具針對性的治療策略。基因測序和生物標記分析技術的進步使得識別多種癌症類型中具有臨床意義的突變變得更加容易。同時，標靶治療和伴隨診斷的日益普及促使醫院和腫瘤中心將分子檢測納入其常規癌症治療和管理策略。

詳細的腫瘤檢查高成本

高成本、高精度的腫瘤檢測仍然是「腫瘤精準醫療和液態生物檢體市場」的潛在阻礙因素。基因測序、分子譜分析、生物標記評估以及專業的診斷基礎設施都需要大量資金。檢查室處理、複雜基因組數據解讀以及聘請專業人員等相關成本會進一步增加檢測費用。在保險覆蓋範圍有限或先進診斷服務不足的地區，醫療機構在採用這些技術方面可能面臨挑戰。因此，經濟障礙可能會限制小規模醫療機構和需要個人化癌症治療的患者獲得檢測服務。

擴大多種癌症的早期檢測範圍

多癌種早期檢測方法的發展為「腫瘤精準醫療和液態生物檢體市場」帶來了機會。利用血液進行液態生物檢體可以檢測循環腫瘤DNA和其他生物標記物，從而有可能揭示與多種癌症相關的分子訊號。定序技術、生物標記識別和人工智慧的進步有望提高早期檢測癌症相關模式的準確性。透過持續的臨床研究和檢驗，液態生物檢體的應用範圍有望從治療監測擴展到更廣泛的患者群體，包括早期癌症檢測和風險評估。

監管和臨床檢驗的挑戰

監管要求和廣泛的臨床檢驗需求可能對腫瘤精準醫療和液態生物檢體市場構成挑戰。分子診斷和液態生物檢體平台必須在廣泛應用前證明其可靠的分析性能、臨床有效性和實際臨床效用。各國法規結構的差異會增加合規要求、延長研發週期並增加相關成本。此外，新發現的生物標記證據有限也會使監管評估更加複雜。這些因素可能導致產品上市延遲、投資風險增加，並使新興腫瘤技術的商業化更加困難。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對癌症篩檢、診斷、治療和研究活動產生了重大影響，並波及癌症精準醫療和液態生物檢體市場。根據世界衛生組織統計，2020年，42%的調查對象國家癌症治療服務受到影響；美國國家癌症研究所（NCI）報告稱，癌症臨床試驗的參與者招募人數大幅下降。由於偵測延誤和醫療資源限制，診斷活動一度受到限制。另一方面，對微創監測和靈活照護模式的需求增加，進一步提升了人們對液態生物檢體和分子檢測技術的關注。

在預測期內，循環腫瘤 DNA (ctDNA) 細分市場預計將佔據最大的市場佔有率。

循環腫瘤DNA (ctDNA) 片段預計將在預測期內佔據最大的市場佔有率，這主要得益於其在癌症分子評估和監測中的廣泛應用。透過血液檢測，ctDNA 無需進行侵入性組織取樣即可提供有關腫瘤相關基因改變的資訊。其應用包括識別具有治療價值的突變、評估治療反應、檢測分子殘留病灶以及追蹤癌症進展。基因測序和先進分子診斷技術的日益普及進一步提升了 ctDNA 在精準腫瘤學和液態生物檢體應用中的重要性。

在預測期內，「監測和復發檢測」細分市場預計將呈現最高的複合年成長率。

在預測期內，「監測和復發檢測」細分市場預計將呈現最高的成長率，這主要得益於癌症持續監測應用的不斷擴展。液態生物檢體能夠對循環腫瘤DNA及相關生物標記進行重複分析，有助於評估治療反應、識別分子水平突變以及預測潛在的疾病復發。定序靈敏度的提高和微量殘存疾病）評估技術的進步正在擴大其在治療後後續觀察的作用。對早期分子層面識別和個人化追蹤的日益重視預計將進一步推動對這些監測應用的需求。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其完善的癌症醫療體系、廣泛的基因組檢測以及成熟的個人化醫療能力。強大的臨床研究基礎設施和先進的分子診斷技術正在加速腫瘤學領域基於生物標記的方法的應用。該地區還擁有眾多專業的癌症醫療機構和診斷實驗室，為液態生物檢體的引入提供了支援。此外，高度發展的製藥和生物技術產業正在推動精準腫瘤學技術和液態生物檢體解決方案在整個醫療保健領域的創新、臨床檢驗和應用。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於癌症負擔的加重、醫療保健體系的改善以及分子診斷技術的普及。基因組檢測、個人化癌症治療和液態生物檢體等領域的投資增加正在推動該地區的發展。新興經濟體醫療保健覆蓋範圍的擴大正在推動這些技術的普及，而對個人化癌症治療日益成長的臨床需求則創造了更多機會。生物技術研究、診斷基礎設施和先進分子平台的進步預計將進​​一步推動該地區市場的持續擴張。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球腫瘤精準醫療與液態生物檢體市場：依生物標記類型分類

  • 循環腫瘤DNA（ctDNA）
  • 循環性腫瘤細胞（CTCs）
  • 外泌體和細胞外囊泡
  • RNA生物標記
  • 蛋白質生物標記

第6章 腫瘤精準醫療和液態生物檢體的全球市場：依癌症類型分類

  • 乳癌
  • 肺癌
  • 結腸癌
  • 攝護腺癌
  • 骨髓惡性腫瘤
  • 其他固體癌

第7章：全球腫瘤精準醫療與液態生物檢體市場：依技術分類

  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應（PCR）
  • 數位PCR
  • 原位雜合反應（ISH）
  • 免疫組織化學（IHC）
  • 微陣列
  • 其他新興技術

第8章 全球腫瘤精準醫療與液態生物檢體市場：依應用領域分類

  • 診斷
  • 預後診斷
  • 伴隨診斷
  • 監測和復發檢測
  • 篩檢

第9章：全球腫瘤精準醫療與液態生物檢體市場：依最終使用者分類

  • 醫院和診所
  • 診斷檢查室
  • 學術研究機構
  • 製藥和生物技術公司

第10章：全球腫瘤精準醫療與液態生物檢體市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN NV
  • Myriad Genetics, Inc.
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • NeoGenomics Laboratories
  • Menarini Silicon Biosystems
  • Natera
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • CelLBxHealth PLC
  • Tempus AI
  • SOPHiA GENETICS
  • Freenome
Product Code: SMRC39748

According to Stratistics MRC, the Global Oncology Precision Medicine & Liquid Biopsy Market is accounted for $6.7 billion in 2026 and is expected to reach $40.7 billion by 2034 growing at a CAGR of 25.2% during the forecast period. Oncology Precision Medicine & Liquid Biopsy combines personalized cancer care with advanced molecular testing to guide treatment based on the biological features of tumors. The approach uses genomic information, biomarkers, and liquid biopsy methods to detect clinically relevant alterations and evaluate changes in cancer over time. By examining circulating tumor DNA and related markers in blood, liquid biopsies provide minimally invasive opportunities for diagnosis, therapy selection, and monitoring. Together, these technologies enable individualized treatment strategies, ongoing assessment, and improved clinical decision-making across different stages of cancer management.

According to WHO/IARC, an estimated 20.6 million new cancer cases and nearly 10 million cancer deaths occurred globally each year, highlighting the substantial disease burden supporting demand for advanced oncology diagnostics and personalized treatment approaches.

Market Dynamics:

Driver:

Growing demand for personalized cancer treatment

Rising demand for individualized cancer care is supporting the expansion of the Oncology Precision Medicine & Liquid Biopsy Market. Precision oncology helps physicians match treatments with the molecular and genetic profiles of tumors, supporting more targeted therapeutic decisions. Improvements in genomic sequencing and biomarker analysis are making it easier to identify clinically meaningful mutations across diverse cancers. At the same time, growing use of targeted medicines and companion diagnostic technologies is encouraging hospitals and oncology centers to incorporate molecular testing into routine cancer treatment and management strategies.

Restraint:

High cost of precision oncology testing

Expensive precision oncology testing remains a potential limitation for the Oncology Precision Medicine & Liquid Biopsy Market. Genomic sequencing, molecular profiling, biomarker evaluation, and specialized diagnostic infrastructure can require considerable financial resources. Additional expenses related to laboratory processing, interpretation of complex genomic data, and skilled professionals may further increase testing costs. Where reimbursement coverage is limited or advanced diagnostic services are less accessible, healthcare providers may face challenges adopting these technologies. Consequently, financial barriers can restrict utilization among smaller healthcare facilities and patients requiring personalized oncology care.

Opportunity:

Expansion of multi-cancer early detection

Growing development of multi-cancer early detection approaches presents an opportunity for the Oncology Precision Medicine & Liquid Biopsy Market. Blood-based liquid biopsy methods can examine circulating tumor DNA and other biomarkers that may reveal molecular signals linked with different cancers. Progress in sequencing technologies, biomarker identification, and artificial intelligence could strengthen the detection of cancer-associated patterns at earlier stages. With continued clinical research and validation, liquid biopsy applications may extend beyond therapy monitoring to include earlier cancer detection and risk evaluation across wider patient groups.

Threat:

Regulatory and clinical validation challenges

Regulatory requirements and the need for extensive clinical validation may create challenges for the Oncology Precision Medicine & Liquid Biopsy Market. Molecular diagnostics and liquid biopsy platforms need to establish dependable analytical performance, clinical validity, and practical clinical usefulness before widespread adoption. Variations in regulatory frameworks between countries can increase compliance requirements, development periods, and associated expenses. Additionally, limited evidence surrounding newly identified biomarkers can complicate regulatory evaluation. Such factors may postpone product launches, increase investment risks, and make commercialization of emerging oncology technologies more difficult.

Covid-19 Impact:

The COVID-19 outbreak significantly affected cancer screening, diagnosis, treatment, and research activities, influencing the oncology precision medicine and liquid biopsy market. According to WHO, cancer treatment services were disrupted in 42% of surveyed countries during 2020, while the NCI reported major reductions in enrollment across cancer clinical trials. Delayed procedures and constrained healthcare resources temporarily limited diagnostic activity. At the same time, demand for less invasive monitoring and adaptable care models encouraged greater attention toward liquid biopsy and molecular testing technologies.

The circulating tumor DNA (ctDNA) segment is expected to be the largest during the forecast period

The circulating tumor DNA (ctDNA) segment is expected to account for the largest market share during the forecast period, supported by its extensive use in molecular cancer assessment and monitoring. Through blood-based testing, ctDNA can provide information about tumor-related genetic changes without requiring invasive tissue collection. Its applications include identifying actionable alterations, evaluating therapeutic response, detecting molecular residual disease, and tracking cancer progression. Growing adoption of genomic sequencing and advanced molecular diagnostic techniques continues to enhance the importance of ctDNA within precision oncology and liquid biopsy applications.

The monitoring & recurrence detection segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the monitoring & recurrence detection segment is predicted to witness the highest growth rate, driven by expanding applications for continuous cancer monitoring. Liquid biopsy allows repeated analysis of circulating tumor DNA and related biomarkers, helping evaluate therapeutic response, identify molecular changes, and recognize possible disease recurrence. Improvements in sequencing sensitivity and minimal residual disease assessment are broadening its role in post-treatment surveillance. Growing emphasis on early molecular identification and individualized patient follow-up is expected to further strengthen demand for these monitoring applications.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by developed cancer-care systems, widespread genomic testing, and established personalized medicine capabilities. Strong clinical research infrastructure and advanced molecular diagnostics facilitate the use of biomarker-guided approaches in oncology. The region also has numerous specialized cancer institutions and diagnostic laboratories that support liquid biopsy adoption. In addition, its well-developed pharmaceutical and biotechnology sectors encourage innovation, clinical validation, and implementation of precision oncology technologies and liquid biopsy solutions throughout healthcare settings.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rising cancer burden, improving healthcare systems, and wider use of molecular diagnostic technologies. Increasing investments in genomic testing, personalized oncology, and liquid biopsy are strengthening regional development. Expanding healthcare availability in emerging countries is supporting adoption, while growing clinical demand for individualized cancer therapies is creating further opportunities. Improvements in biotechnology research, diagnostic infrastructure, and advanced molecular platforms are expected to reinforce the region's continued market expansion.

Key players in the market

Some of the key players in Oncology Precision Medicine & Liquid Biopsy Market include F. Hoffmann-La Roche Ltd, Guardant Health, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Myriad Genetics, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., NeoGenomics Laboratories, Menarini Silicon Biosystems, Natera, Abbott Laboratories, Adaptive Biotechnologies, CelLBxHealth PLC, Tempus AI, SOPHiA GENETICS and Freenome.

Key Developments:

In November 2025, Abbott and Exact Sciences announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.

In October 2025, Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials. The deal includes potential additional earnout and other payments contingent on future performance. Clario's platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence across all phases of drug development.

Biomarker Types Covered:

  • Circulating Tumor DNA (ctDNA)
  • Circulating Tumor Cells (CTCs)
  • Exosomes & Extracellular Vesicles
  • RNA Biomarkers
  • Protein Biomarkers

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Hematological Malignancies
  • Other Solid Tumors

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Digital PCR
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Microarrays
  • Other Emerging Technologies

Applications Covered:

  • Diagnostics
  • Prognostics
  • Companion Diagnostics
  • Monitoring & Recurrence Detection
  • Screening

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Oncology Precision Medicine & Liquid Biopsy Market, By Biomarker Type

  • 5.1 Circulating Tumor DNA (ctDNA)
  • 5.2 Circulating Tumor Cells (CTCs)
  • 5.3 Exosomes & Extracellular Vesicles
  • 5.4 RNA Biomarkers
  • 5.5 Protein Biomarkers

6 Global Oncology Precision Medicine & Liquid Biopsy Market, By Cancer Type

  • 6.1 Breast Cancer
  • 6.2 Lung Cancer
  • 6.3 Colorectal Cancer
  • 6.4 Prostate Cancer
  • 6.5 Hematological Malignancies
  • 6.6 Other Solid Tumors

7 Global Oncology Precision Medicine & Liquid Biopsy Market, By Technology

  • 7.1 Next-Generation Sequencing (NGS)
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Digital PCR
  • 7.4 In Situ Hybridization (ISH)
  • 7.5 Immunohistochemistry (IHC)
  • 7.6 Microarrays
  • 7.7 Other Emerging Technologies

8 Global Oncology Precision Medicine & Liquid Biopsy Market, By Application

  • 8.1 Diagnostics
  • 8.2 Prognostics
  • 8.3 Companion Diagnostics
  • 8.4 Monitoring & Recurrence Detection
  • 8.5 Screening

9 Global Oncology Precision Medicine & Liquid Biopsy Market, By End User

  • 9.1 Hospitals & Clinics
  • 9.2 Diagnostic Laboratories
  • 9.3 Academic & Research Institutes
  • 9.4 Pharmaceutical & Biotechnology Companies

10 Global Oncology Precision Medicine & Liquid Biopsy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd
  • 13.2 Guardant Health
  • 13.3 Illumina, Inc.
  • 13.4 Thermo Fisher Scientific Inc.
  • 13.5 QIAGEN N.V.
  • 13.6 Myriad Genetics, Inc.
  • 13.7 Sysmex Corporation
  • 13.8 Bio-Rad Laboratories, Inc.
  • 13.9 Agilent Technologies, Inc.
  • 13.10 NeoGenomics Laboratories
  • 13.11 Menarini Silicon Biosystems
  • 13.12 Natera
  • 13.13 Abbott Laboratories
  • 13.14 Adaptive Biotechnologies
  • 13.15 CelLBxHealth PLC
  • 13.16 Tempus AI
  • 13.17 SOPHiA GENETICS
  • 13.18 Freenome

List of Tables

  • Table 1 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Biomarker Type (2023-2034) ($MN)
  • Table 3 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Circulating Tumor DNA (ctDNA) (2023-2034) ($MN)
  • Table 4 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Circulating Tumor Cells (CTCs) (2023-2034) ($MN)
  • Table 5 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Exosomes & Extracellular Vesicles (2023-2034) ($MN)
  • Table 6 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By RNA Biomarkers (2023-2034) ($MN)
  • Table 7 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Protein Biomarkers (2023-2034) ($MN)
  • Table 8 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Cancer Type (2023-2034) ($MN)
  • Table 9 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 10 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Lung Cancer (2023-2034) ($MN)
  • Table 11 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 12 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Prostate Cancer (2023-2034) ($MN)
  • Table 13 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Hematological Malignancies (2023-2034) ($MN)
  • Table 14 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Other Solid Tumors (2023-2034) ($MN)
  • Table 15 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Technology (2023-2034) ($MN)
  • Table 16 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 17 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 18 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Digital PCR (2023-2034) ($MN)
  • Table 19 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By In Situ Hybridization (ISH) (2023-2034) ($MN)
  • Table 20 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Immunohistochemistry (IHC) (2023-2034) ($MN)
  • Table 21 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Microarrays (2023-2034) ($MN)
  • Table 22 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Other Emerging Technologies (2023-2034) ($MN)
  • Table 23 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Application (2023-2034) ($MN)
  • Table 24 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Diagnostics (2023-2034) ($MN)
  • Table 25 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Prognostics (2023-2034) ($MN)
  • Table 26 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Companion Diagnostics (2023-2034) ($MN)
  • Table 27 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Monitoring & Recurrence Detection (2023-2034) ($MN)
  • Table 28 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Screening (2023-2034) ($MN)
  • Table 29 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By End User (2023-2034) ($MN)
  • Table 30 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 31 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 32 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 33 Global Oncology Precision Medicine & Liquid Biopsy Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.